Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Opioid dependence and HIV/AIDS are 2 of the most serious yet treatable diseases worldwide. Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur. METHODS: We reviewed English, Spanish, French, and Italian language articles from 1966 to 2005 in Medline using the following keywords: HIV, AIDS, HIV therapy, antiretroviral therapy, HAART, drug interactions, methadone, and buprenorphine. Additionally, we reviewed abstracts from national and international meetings and conference proceedings. Selected references from these articles were reviewed as well. RESULTS: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone and most approved antiretroviral therapies. Important pharmacokinetic drug interactions have been demonstrated within each class of agents, affecting either methadone or antiretroviral agents. Few studies, however, have been conducted with buprenorphine. The metabolism of both therapies, description of the known interactions, and clinical implications and management of these interactions are reviewed. CONCLUSIONS: Certain interactions between methadone and antiretroviral medications are known and may have important clinical consequences. To optimize care, clinicians must be alert to these interactions and have a basic knowledge regarding their management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eap, C. B., Buclin, T., & Baumann, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00003 · Cited by 599
Office-Based Treatment of Opioid-Dependent Patients
Fiellin, D. A., & O'Connor, P. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp013579 · Cited by 148
Cited by
Altice, F. L., Kamarulzaman, A., Soriano, V. V., Schechter, M., & Friedland, G. H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60829-x · Cited by 504
Self-citationEap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Déglon, J.-J., Besson, J., Croquette-Krokar, M., Carrupt, P.-A., & Abriel, H. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100120 · Cited by 255
Role of CYP2B6 in Stereoselective Human Methadone Metabolism
Totah, R. A., Sheffels, P., Roberts, T., Whittington, D., Thummel, K., & Kharasch, E. D. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181642938 · Cited by 192
“There is also a potential for CYP2B6-mediated drug–drug interactions, causing either induction or inhibition of methadone metabolism and clearance, exemplified by methadone interactions with antiretrovirals, antifungals, and antiepileptics.(4,47,48) In summary, these results show that CYP3A4 and CYP2B6 but not CYP2C19…”
BackgroundPharmacotherapy in the Treatment of Addiction: Methadone
Kreek, M. J., Borg, L., Ducat, E., & Ray, B. (2010) · Journal of Addictive Diseases · doi:10.1080/10550881003684798 · Cited by 108
Green, T. C., Kershaw, T., Lin, H., Heimer, R., Goulet, J. L., Kraemer, K. L., Gordon, A. J., Maisto, S. A., Day, N. L., Bryant, K., et al. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.02.020 · Cited by 101
Metadata
- Authors
- Bruce, R. D., Altice, F. L., Gourevitch, M. N., & Friedland, G. H.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2006-04-15
- Volume
- 41
- Issue
- 5
- Pages
- 563-572
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W1974463788
- Cited by
- 106
- References
- 2
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice. https://app.cochat.ai/papers/10.1097/01.qai.0000219769.89679.ec
- The paper
- Bruce, R. D., Altice, F. L., Gourevitch, M. N., & Friedland, G. H. (2006). Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/01.qai.0000219769.89679.ec
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.